Silence Therapeutics plc, a London-based biotech firm specializing in RNAi therapeutics, reported significant deterioration in operating and net income for 2025, with operating losses widening by nearly 44% year-over-year and net losses almost doubling. Despite a sharp revenue drop previously reported in mid-2025, the company maintains strong liquidity with a current ratio above 8, supporting its continued R&D investments. The recent transition to U.S. issuer status on Nasdaq marks a strategic move expected to enhance capital access amid ongoing cash burn. Cybersecurity risk management remains a key governance focus during this pivotal phase. Going forward, pipeline progress and capital preservation will be critical milestones to monitor.